Primary, secondary, and tertiary hyperparathyroidism

Otolaryngologic Clinics of North America

Volumn 37, Issue 4, 2004, Pages 701-713

  Ahmad, Rehan ^a,b   Hammond, James M ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CINACALCET; ERGOCALCIFEROL; LITHIUM; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARICALCITOL; PHOSPHORUS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE DISEASE; CLINICAL FEATURE; EUROPE; EVALUATION; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; KIDNEY FAILURE; LABORATORY TEST; MORBIDITY; NEPHROLITHIASIS; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; REVIEW; SKELETON; THYMECTOMY; UNITED STATES; VITAMIN D DEFICIENCY; VOMITING;

HUMANS; HYPERPARATHYROIDISM; HYPERPARATHYROIDISM, SECONDARY;

EID: 3242714126     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2004.02.004     Document Type: Review

References (57)

1. Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 274:1966;1174
2. Heath H. III, Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 302:1980;189
3. Mundy G.R., Cove D.H., Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet. 1:1980;1317
4. Davies D.R., Dent C.E., Watson L. Tertiary hyperparathyroidism. BMJ. 2:1968;395
5. Melton L.J. III. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res. 17:(Suppl 2):2002;N12
6. Wermers R.A., Khosla S., Atkinson E.J., Hodgson S.F., O'Fallon W.M., Melton L.J. III. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 126:1997;433
7. Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 17:(Suppl 2):2002;N18
8. Salti G.I., Fedorak I., Yashiro T., Fulton N., Hara H., Yousefzadeh D., et al. Continuing evolution in the operative management of primary hyperparathyroidism. Arch Surg. 127:1992;831
9. Bartsch D., Nies C., Hasse C., Willuhn J., Rothmund M. Clinical and surgical aspects of double adenoma in patients with primary hyperparathyroidism. Br J Surg. 82:1995;926
10. Wynne A.G., van Heerden J., Carney J.A., Fitzpatrick L.A. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 71:1992;197
11. Brown E.M. The pathophysiology of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N24
12. Arnold A., Shattuck T.M., Mallya S.M., Krebs L.J., Costa J., Gallagheret J., et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N30
13. Marx S.J., Simonds W.F., Agarwal S.K., Burns A.L., Weinstein L.S., Cochran C., et al. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 17:(Suppl 2):2002;N37
14. Silverberg S.J., Bilezikian J.P. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1996;2036
15. Williams R.H., Larsen P.R. Williams textbook of endocrinology. 10th edition :2003;Saunders, Philadelphia
16. Silverberg S.J., Bilezikian J.P. Primary hyperparathyroidism: still evolving? J Bone Miner Res. 12:1997;856
17. Lundgren E., Ljunghall S., Akerstrom G., Hetta J., Mallmin H., Rastad J. Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery. 124:1998;980
18. Chan A.K., Duh Q.Y., Katz M.H., Siperstein A.E., Clark O.H. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg. 222:1995;402
19. Lundgren E., Szabo E., Ljunghall S., Bergstrom R., Holmberg L., Rastad J. Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism. BMJ. 317:1998;848
20. McAllion S.J., Paterson C.R. Psychiatric morbidity in primary hyperparathyroidism. Postgrad Med J. 65:1989;628
21. Joborn C., Hetta J., Palmer M., Akerstrom G., Ljunghall S. Psychiatric symptomatology in patients with primary hyperparathyroidism. Ups J Med Sci. 91:1986;77
22. Silverberg S.J. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin N Am. 29:2000;451
23. Silverberg S.J. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N117
24. Silverberg S.J., Shane E., Jacobs T.P., Siris E., Bilezikian J.P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 341:1999;1249
25. Silverberg S.J., Shane E., Jacobs T.P., Siris E.S., Gartenberg F., Seldin D., et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med. 89:1990;327
26. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res. 17:(Suppl 2):2002;N87
27. Khosla S., Melton L.J. III, Wermers R.A., Crowson C.S., O'Fallon W., Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 14:1999;1700
28. Einhorn T.A. Bone strength: the bottom line. Calcif Tissue Int. 51:1992;333
29. Silverberg S.J., Shane E., de la Cruz L., Dempster D.W., Feldman F., Seldin D., et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 4:1989;283
30. Miller P.D., Bilezikian J.P. Bone densitometry in asymptomatic primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N98
31. Silverberg S.J., Locker F.G., Bilezikian J.P. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab. 81:1996;4007
32. Siperstein A.E., Shen W., Chan A.K., Duh Q.Y., Clark O.H. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg. 127:1992;1157
33. Gao P., Scheibel S., D'Amour P., John M.R., Rao S.D., Schmidt-Gayk H., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 16:2001;605
34. Bilezikian J.P., Potts J.T. Jr., Fuleihan Gel H., Kleerekoper M., Neer R., Peacock M., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 87:2002;5353
35. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 235:2002;665
36. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 86:2001;5658
37. Locker F.G., Silverberg S.J., Bilezikian J.P. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med. 102:1997;543
38. Cosman F., Shen V., Xie F., Seibel M., Ratcliffe A., Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med. 118:1993;337
39. Marcus R. The role of estrogens and related compounds in the management of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N146
40. Rubin M.R., Lee K.H., McMahon D.J., Silverberg S.J. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 88:2003;1174
41. Rossini M., Gatti D., Isaia G., Sartori L., Braga V., Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 16:2001;113
42. Chow C.C., Chan W.B., Li J.K., Chan N.N., Chan M.H., Ko G.T., et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 88:2003;581
43. Parker C.R., Blackwell P.J., Fairbairn K.J., Hosking D.J. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 87:2002;4482
44. Frazao J.M., Martins P., Coburn J.W. The calcimimetic agents: perspectives for treatment. Kidney Int Suppl. 80:2002;149
45. Antoniucci D.M., Shoback D. Calcimimetics in the treatment of primary hyperparathyroidism. J Bone Miner Res. 17:(Suppl 2):2002;N141
46. Malberti F., Marcelli D., Conte F., Limido A., Spotti D., Locatelli F. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol. 12:2001;1242
47. Harris S.S., Soteriades E., Dawson-Hughes B. Secondary hyperparathyroidism and bone turnover in elderly blacks and whites. J Clin Endocrinol Metab. 86:2001;3801
48. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 338:1998;777
49. Llach F., Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis. 38:2001;S20
50. Gogusev J., Duchambon P., Hory B., Giovannini M., Goureau Y., Sarfati E., et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51:1997;328
51. Indridason O.S., Heath H. III, Khosla S., Yohay D.A., Quarles L.D. Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism. Kidney Int. 50:1996;1663
52. Lloyd H.M., Parfitt A.M., Jacobi J.M., Willgoss D.A., Craswell P.W., Petrie J.J., et al. The parathyroid glands in chronic renal failure: a study of their growth and other properties made on the basis of findings in patients with hypercalcemia. J Lab Clin Med. 114:1989;358
53. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 342:2000;1478
54. Sprague S.M., Llach F., Amdahl M., Taccetta C., Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63:2003;1483
55. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 349:2003;446
56. Quarles L.D., Sherrard D.J., Adler S., Rosansky S.J., McCary L.C., Liu W., et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 14:2003;575
57. Fukagawa M., Kitaoka M., Tominaga Y., Akizawa T., Kakuta T., Onoda N., et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant. 18:(Suppl 3):2003;iii-31